The expression of miR-126 can be enhanced by negatively regulating the VEGF/PI3K/Akt/MRP1 signaling pathway, which can increase the sensitivity of NSCLC cells to anticancer drugs [33]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.